A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
15actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-10 | actual | When the study began enrolling |
| Primary completion | 2026-01-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus
Intervention
- Drug: LY3209590
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3209590
measured Predose up to 65 days post dose
PK: Maximum Observed Plasma Concentration (Cmax) of LY3209590
measured Predose up to 65 days post dose
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed